Sarcoidosis is a multisystemic disorder that is characterized by the formation of noncaseating granulomas. Although sarcoidosis can affect any organ, gastrointestinal tract involvement in sarcoidosis is very rare, and gastric cancer associated with gastric sarcoidosis has hardly been reported. A 64-year-old female with a 10-year history of the medical treatment of gastric sarcoidosis received a...

old world cutaneous leishmaniasis (owcl) usually causes a single, self-healing and uncomplicated lesion mainly on the exposed area of body. this report presents four cases of owcl from iran that misdiagnosed with sarcoidosis, lymphoma, and acne agminata. two out of four patients showed a history of purplish red plaques for at least 5 years who misdiagnosed as sarcoidosis because of histological...

Abstract Background The new guidelines limited the use of lung biopsy in evaluation fibrosis because its hazards. differential diagnosis interstitial pulmonary (IPF) or usual pneumonia (UIP) is challenging overlapping multi-detector computed tomography (MDCT) morphologic features between and non-interstitial fibrosing diseases. Scar carcinoma a serious complication that needs to be excluded cer...

STUDY OBJECTIVES To describe the population of patients with sarcoidosis listed for orthotopic lung transplantation (OLT) in the United States, and to determine outcomes for these subjects relative to persons awaiting OLT for idiopathic pulmonary fibrosis (IPF). DESIGN Retrospective analysis of the United Network for Organ Sharing transplant database over the period between January 1995 and D...

Cardiac sarcoidosis is an underdiagnosed disease that may be present in as many as 25% of patients with systemic sarcoidosis. Although most commonly recognized in patients with other manifestations of sarcoidosis, it may occur in isolation and its presence is often not appreciated. Cardiac sarcoidosis may present as asymptomatic left ventricular dysfunction, congestive heart failure, atrioventr...

Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials 3 Hot on the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good 4 Idiopathic Pulmonary Fibrosis: Lung Function is a Clinically Meaningful Endpoint for Phase 3 Trials 4 III. About Sarcoidosis 5 A Novel Sarcoidosis Risk Locus for Europeans on Chromosom...

INTRODUCTION Sarcoidosis is a multisystemic inflammatory disease with myriad clinical manifestations. Neurologic involvement in sarcoidosis is uncommon. Peripheral neuropathic presentations include mononeuropathy, mononeuritis multiplex, and generalized sensory, motor, autonomic, and sensorimotor polyneuropathies. CASE PRESENTATION We report a case of carpal tunnel syndrome caused by sarcoido...

BACKGROUND Infliximab, a TNF-alpha blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. DESIGN Case-report. RESULTS AND CONCLUSIONS A patient with severe earlobe sarcoidosis, treated with infliximab, is pr...

Sarcoidosis is an inflammatory disease involving multiple-organs with an unknown cause. The new onset of sarcoidosis associated with therapeutic agents has been observed in 3 clinical settings; tumor necrosis factor antagonists in autoimmune rheumatologic diseases, interferon alpha with or without ribavirin in patients with chronic hepatitis C or melanoma, and antineoplastic agent-associated sa...

Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed ...